1464 related articles for article (PubMed ID: 28883282)
1. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
2. [Anti-PD-1 antibody and anti-PD-Li antibody -from basic and clinic-].
Kitano S
Nihon Rinsho; 2017 Feb; 75(2):201-207. PubMed ID: 30562853
[TBL] [Abstract][Full Text] [Related]
3. Clinical Development of Immune Checkpoint Inhibitors.
Ito A; Kondo S; Tada K; Kitano S
Biomed Res Int; 2015; 2015():605478. PubMed ID: 26161407
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
10. [Development of immune checkpoint inhibitor in colorectal cancer].
Kitano S
Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
[TBL] [Abstract][Full Text] [Related]
11. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
12. Current status of immunotherapy.
Suzuki S; Ishida T; Yoshikawa K; Ueda R
Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
14. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
Hatae R; Chamoto K
Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
18. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Luke JJ; Ott PA
Oncotarget; 2015 Feb; 6(6):3479-92. PubMed ID: 25682878
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez-Rodas I; Cerezuela P; Soria A; Berrocal A; Riso A; González-Cao M; Martín-Algarra S
Ann Transl Med; 2015 Oct; 3(18):267. PubMed ID: 26605313
[TBL] [Abstract][Full Text] [Related]
20. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
